Short‐Term exposure of umbilical cord blood CD34+ cells to human platelet lysate and cytokines enhances engraftment
- 5 August 2020
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 60 (10) , 2348-2358
Abstract
Background: Intra bone marrow (IBM) injection has been proposed as a strategy to bypass homing inefficiencies associated with intravenous (IV) hematopoietic progenitor stem cell (HSPC) transplantation and thus increases the number of HSPC that engraft. Despite physical delivery into the bone marrow cavity, many donor cells are rapidly redistributed by vascular perfusion. Thus, the objective of our study was to evaluate the ability of human platelet lysates (hPL) to improve HSPC retention into the bone marrow and consequently to improve engraftment.Study Design and Methods: HSPC were isolated from human umbilical cord blood. HSPC were seeded in the wells of a 24‐well microplate and exposed to increasing concentrations of hPL with or without cytokines for 24 hours. Following priming, HSPC cells chemotaxis to rhSDF‐1 was determined in vitro and engraftment in NSG mice was evaluated.Results: Priming of cord blood CD34+ cells to a combination of hPL and cytokines resulted in a significant increase (up to 3‐fold) in the expression of the CD34 antigen on HSPC. This effect was closely correlated to a significantly increased (up to 7‐fold) migration toward a rhSDF‐1 concentration gradient. In addition, IBM injection of CD34+ cells previously primed with hPL+cytokines into NSG mice showed significantly increased engraftment as measured by human platelet numbers, human CD45 and human CD34+ cells for unprimed and primed cells, respectively.Conclusion: The use of hPL + cytokines as a short‐term priming treatment for UCB could be an advantageous strategy to improve clinical outcomes following IBM injection.Keywords
This publication has 31 references indexed in Scilit:
- Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft SourcesTransplantation and Cellular Therapy, 2014
- Umbilical cord blood transplantation: the first 25 years and beyondBlood, 2013
- Unrelated Cord Blood TransplantationTransplantation, 2013
- Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell CocultureNew England Journal of Medicine, 2012
- Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissionsBlood, 2011
- Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitutionNature Medicine, 2010
- Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II studyThe Lancet Oncology, 2008
- Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancyBlood, 2005
- Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantationBlood, 2004
- Creation of a Double Chimera after the Transplantation of Umbilical-Cord Blood from Two Partially Matched Unrelated DonorsNew England Journal of Medicine, 2001